Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial
暂无分享,去创建一个
Jasmin A. Tiro | E. Halm | C. Skinner | C. Murphy | J. Tiro | A. Singal | Samir Gupta | N. Santini | D. Agrawal | J. Sanders | W. Bishop | Katharine McCallister | Chul Ahn | Christian Mayorga | Adam C. Loewen | Noel O. Santini
[1] T. Thompson,et al. Cancer Screening Test Use — United States, 2015 , 2017, MMWR. Morbidity and mortality weekly report.
[2] M. Gold. Cost-effectiveness in health and medicine , 2016 .
[3] M. Pignone,et al. Multilevel predictors of colorectal cancer testing modality among publicly and privately insured people turning 50 , 2016, Preventive medicine reports.
[4] M. Phipps,et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. , 2016, JAMA.
[5] Jasmin A. Tiro,et al. Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety‐net health system , 2016, Cancer.
[6] E. Halm,et al. Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems , 2016, Cancer Epidemiology, Biomarkers and Prevention.
[7] Alison R. T. Brenner,et al. Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years , 2016, The American Journal of Gastroenterology.
[8] E. Halm,et al. Predictors of guideline concordance for surveillance colonoscopy recommendations in patients at a safety-net health system , 2015, Cancer Causes & Control.
[9] A. Jemal,et al. Elimination of cost‐sharing and receipt of screening for colorectal and breast cancer , 2015, Cancer.
[10] Chyke A Doubeni,et al. How Can We Boost Colorectal and Hepatocellular Cancer Screening Among Underserved Populations? , 2015, Current Gastroenterology Reports.
[11] P. Bossuyt,et al. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening. , 2015, Cancer epidemiology.
[12] Fernando A. Wilson,et al. Cost-Effectiveness Analysis of a Colonoscopy Screening Navigator Program Designed for Hispanic Men , 2015, Journal of Cancer Education.
[13] Yinghui Xu,et al. Comparison of patient preferences for fecal immunochemical test or colonoscopy using the analytic hierarchy process , 2015, BMC Health Services Research.
[14] S. Vernon,et al. Results of Nurse Navigator Follow-up After Positive Colorectal Cancer Screening Test: A Randomized Trial , 2014, The Journal of the American Board of Family Medicine.
[15] M. Wolf,et al. Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: a randomized clinical trial. , 2014, JAMA internal medicine.
[16] Yingye Zheng,et al. The Colorectal Cancer Screening Process in Community Settings: A Conceptual Model for the Population-Based Research Optimizing Screening through Personalized Regimens Consortium , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[17] D. Ransohoff,et al. Multitarget stool DNA testing for colorectal-cancer screening. , 2014, The New England journal of medicine.
[18] B. Farham. Quantification of harms in cancer screening trials: Literature review , 2013 .
[19] Jasmin A. Tiro,et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. , 2013, JAMA Internal Medicine.
[20] J. Le Breton,et al. Colorectal cancer screening: factors associated with colonoscopy after a positive faecal occult blood test , 2013, British Journal of Cancer.
[21] C. Messina,et al. Clinical case management and navigation for colonoscopy screening in an academic medical center , 2013, Cancer.
[22] B. Denis,et al. Harms of colonoscopy in a colorectal cancer screening programme with faecal occult blood test: a population-based cohort study. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[23] M. Schluchter,et al. Use of colonoscopy for polyp surveillance in Medicare beneficiaries , 2013, Cancer.
[24] J. Feinglass,et al. Adherence to Repeat Fecal Occult Blood Testing in an Urban Community Health Center Network , 2013, Journal of Community Health.
[25] E. Emanuel,et al. Shared decision making to improve care and reduce costs. , 2013, The New England journal of medicine.
[26] L. K. Bartholomew,et al. Preferences for colorectal cancer screening tests and screening test use in a large multispecialty primary care practice , 2012, Cancer.
[27] Angela Fagerlin,et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. , 2012, Archives of internal medicine.
[28] M. Barry,et al. Shared decision making--pinnacle of patient-centered care. , 2012, The New England journal of medicine.
[29] Á. Lanas,et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. , 2012, The New England journal of medicine.
[30] J. Habbema,et al. Fecal occult blood testing when colonoscopy capacity is limited. , 2011, Journal of the National Cancer Institute.
[31] B. Leggett,et al. Repeat participation in colorectal cancer screening utilizing fecal occult blood testing: A community‐based project in a rural setting , 2010, Journal of gastroenterology and hepatology.
[32] Joann G Elmore,et al. Longitudinal Adherence With Fecal Occult Blood Test Screening in Community Practice , 2010, The Annals of Family Medicine.
[33] H. Brenner,et al. Protection from colorectal cancer after colonoscopy: Population-based case-control study , 2010 .
[34] S. Ryu,et al. Comparison of Guaiac-Based and Quantitative Immunochemical Fecal Occult Blood Testing in a Population at Average Risk Undergoing Colorectal Cancer Screening , 2010, The American Journal of Gastroenterology.
[35] D. Jonas,et al. Systematic Review: Enhancing the Use and Quality of Colorectal Cancer Screening , 2010, Annals of Internal Medicine.
[36] Cancer,et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial , 2010, The Lancet.
[37] D. Comaneshter,et al. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use , 2010, Cancer.
[38] S. Taplin,et al. Interfaces across the cancer continuum offer opportunities to improve the process of care. , 2010, Journal of the National Cancer Institute. Monographs.
[39] B. Balluff,et al. Performance of Epigenetic Markers SEPT9 and ALX4 in Plasma for Detection of Colorectal Precancerous Lesions , 2010, PloS one.
[40] B. Hemmelgarn,et al. Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[41] L. Seeff,et al. The impact of detection and treatment on lifetime medical costs for patients with precancerous polyps and colorectal cancer. , 2009, Health economics.
[42] Christian Pilarsky,et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. , 2009, Clinical chemistry.
[43] Sun Hee Rim,et al. Colorectal cancer incidence in the United States, 1999‐2004 , 2009, Cancer.
[44] Hardeep Singh,et al. Using a Multifaceted Approach to Improve the Follow-Up of Positive Fecal Occult Blood Test Results , 2009, The American Journal of Gastroenterology.
[45] Samir Gupta. Will test-specific adherence predict the best colorectal cancer screening strategy? , 2009, Annals of internal medicine.
[46] Sandhya K. Rao,et al. Challenges in the Management of Positive Fecal Occult Blood Tests , 2009, Journal of General Internal Medicine.
[47] L. Rabeneck,et al. Association of Colonoscopy and Death From Colorectal Cancer , 2009, Annals of Internal Medicine.
[48] Rinku Sutradhar,et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. , 2008, Gastroenterology.
[49] C. Pilarsky,et al. Sensitive Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay , 2008, PloS one.
[50] Amy B. Knudsen,et al. Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.
[51] D. Sargent,et al. Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia , 2008, Annals of Internal Medicine.
[52] E. Feuer,et al. Improvement in the Diagnostic Evaluation of a Positive Fecal Occult Blood Test in an Integrated Health Care Organization , 2008, Medical care.
[53] R. Coates,et al. Trends in colorectal cancer screening disparities in people aged 50-64 years, 2000-2005. , 2008, American journal of preventive medicine.
[54] T. Sensky,et al. Systematic Review of the Effects of Shared Decision-Making on Patient Satisfaction, Treatment Adherence and Health Status , 2008, Psychotherapy and Psychosomatics.
[55] E. Emanuel,et al. Quality-improvement research and informed consent. , 2008, The New England journal of medicine.
[56] Terry Hyslop,et al. A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening , 2007, Cancer.
[57] L. Bisanti,et al. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. , 2007, Gastroenterology.
[58] M. Leshno,et al. A Quantitative Immunochemical Fecal Occult Blood Test for Colorectal Neoplasia , 2007, Annals of Internal Medicine.
[59] A. Spigelman. A comparison of colorectal neoplasia screening tests: a multicentre community‐based study of the impact of consumer choice , 2006, The Medical journal of Australia.
[60] D. Fisher,et al. Barriers to Full Colon Evaluation for a Positive Fecal Occult Blood Test , 2006, Cancer Epidemiology Biomarkers & Prevention.
[61] Lisa V Rubenstein,et al. Measuring the Quality of Colorectal Cancer Screening: The Importance of Follow-Up , 2006, Diseases of the colon and rectum.
[62] Donald M Berwick,et al. All-or-none measurement raises the bar on performance. , 2006, JAMA.
[63] A. Sonnenberg,et al. Comparing risks and benefits of colorectal cancer screening in elderly patients. , 2005, Gastroenterology.
[64] A. Schatzkin,et al. Colonoscopic screening of average-risk women for colorectal neoplasia. , 2005, The New England journal of medicine.
[65] D. Ransohoff,et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. , 2004, The New England journal of medicine.
[66] L. Seeff,et al. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States? , 2004, Gastroenterology.
[67] J. Faivre,et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. , 2004, Gastroenterology.
[68] Timothy R Church,et al. A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening. , 2004, Journal of the National Cancer Institute.
[69] Terry Hyslop,et al. Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. , 2004, Preventive medicine.
[70] M. Cowen,et al. The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. , 2003, Archives of internal medicine.
[71] J. Selby,et al. Complications of screening flexible sigmoidoscopy. , 2002, Gastroenterology.
[72] Margaret Maglione,et al. Interventions That Increase Use of Adult Immunization and Cancer Screening Services , 2002, Annals of Internal Medicine.
[73] J. Scholefield,et al. Psychiatric morbidity and screening for colorectal cancer , 2002, Journal of medical screening.
[74] Amnon Sonnenberg,et al. Cost-effectiveness of a single colonoscopy in screening for colorectal cancer. , 2002, Archives of internal medicine.
[75] D. Lieberman,et al. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. , 2001, The New England journal of medicine.
[76] D. Lieberman,et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. , 2000, The New England journal of medicine.
[77] S. Moss,et al. The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer , 1999, Gut.
[78] D. Torgerson,et al. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. , 1999, QJM : monthly journal of the Association of Physicians.
[79] J. Olsen,et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test , 1996, The Lancet.
[80] A. Sonnenberg,et al. Prevention of Colorectal Cancer by Flexible Endoscopy and Polypectomy: A Case-Control Study of 32 702 Veterans , 1995, Annals of Internal Medicine.
[81] G. Friedman,et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. , 1992, The New England journal of medicine.
[82] C. Jepson,et al. Behavioral Interventions to Increase Adherence in Colorectal Cancer Screening , 1991, Medical care.
[83] T. Marteau,et al. Psychological costs of screening. , 1989, BMJ.
[84] T. Taguchi,et al. [Occult blood screening for colorectal cancer]. , 1986, Gan to kagaku ryoho. Cancer & chemotherapy.
[85] Jasmin A. Tiro,et al. Reasons for Lack of Diagnostic Colonoscopy After Positive Result on Fecal Immunochemical Test in a Safety-Net Health System. , 2017, The American journal of medicine.
[86] J. V Schönfeld. [Colonoscopy versus fecal immunochemical testing in colorectal cancer screening]. , 2013, Zeitschrift fur Gastroenterologie.
[87] R. Hayes,et al. Utilization of surveillance colonoscopy in community practice. , 2010, Gastroenterology.
[88] J. Yee,et al. Accuracy of ct colonography for detection of large adenomas and cancers , 2009 .
[89] L. Rabeneck,et al. Endoscopic follow-up of positive fecal occult blood testing in the Ontario FOBT Project. , 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[90] M. Manos,et al. A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[91] D. Rex,et al. Distal colonic hyperplastic polyps do not predict proximal adenomas in asymptomatic average-risk subjects. , 1992, Gastroenterology.
[92] S Kamen,et al. The task force. , 1976, Journal of hospital dental practice.